Amonafide: A future in treatment of resistant and secondary acute myeloid leukemia?

Ciara L. Freeman, Ronan T Swords, Francis J. Giles

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Development of the novel topoisomerase II inhibitor, amonafide, began almost 40 years ago. The drug was selected for further investigation owing to evidence of marked antineoplastic efficacy in preclinical models of cancer. When its usefulness in the treatment of various solid malignancies proved limited, focus was shifted to establishing its use as an antileukemic agent, specifically against secondary and treatment-associated acute myeloid leukemia (AML). While Phase I and II studies gave rise to hopes that amonafide might hold the key to treating older patients, including those with multidrug resistant, cytogenetically unfavorable secondary and treatment-associated AML, when used in combination with cytarabine, it failed to demonstrate a survival advantage over standard-of-care therapy in randomized studies. This article will outline the development of amonafide from the laboratory to the bedside and discuss the potential place that this agent has in the current management of AML.

Original languageEnglish
Pages (from-to)17-26
Number of pages10
JournalExpert Review of Hematology
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

amonafide
Acute Myeloid Leukemia
Topoisomerase II Inhibitors
Cytarabine
Therapeutics
Standard of Care
Antineoplastic Agents
Neoplasms
Survival
Pharmaceutical Preparations

Keywords

  • AML
  • amonafide (l-malate)
  • cytarabine (ARA-C)
  • MDR proteins
  • multidrug resistance
  • N-acetyltransferase 2 (NAT2)
  • naphthalimides
  • P-glycoprotein
  • secondary AML/treatment-related AML (sAML/tAML)
  • topoisomerase II inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Amonafide : A future in treatment of resistant and secondary acute myeloid leukemia? / Freeman, Ciara L.; Swords, Ronan T; Giles, Francis J.

In: Expert Review of Hematology, Vol. 5, No. 1, 01.02.2012, p. 17-26.

Research output: Contribution to journalArticle

Freeman, Ciara L. ; Swords, Ronan T ; Giles, Francis J. / Amonafide : A future in treatment of resistant and secondary acute myeloid leukemia?. In: Expert Review of Hematology. 2012 ; Vol. 5, No. 1. pp. 17-26.
@article{b7e74b4a861e4326a0d27d27c247734c,
title = "Amonafide: A future in treatment of resistant and secondary acute myeloid leukemia?",
abstract = "Development of the novel topoisomerase II inhibitor, amonafide, began almost 40 years ago. The drug was selected for further investigation owing to evidence of marked antineoplastic efficacy in preclinical models of cancer. When its usefulness in the treatment of various solid malignancies proved limited, focus was shifted to establishing its use as an antileukemic agent, specifically against secondary and treatment-associated acute myeloid leukemia (AML). While Phase I and II studies gave rise to hopes that amonafide might hold the key to treating older patients, including those with multidrug resistant, cytogenetically unfavorable secondary and treatment-associated AML, when used in combination with cytarabine, it failed to demonstrate a survival advantage over standard-of-care therapy in randomized studies. This article will outline the development of amonafide from the laboratory to the bedside and discuss the potential place that this agent has in the current management of AML.",
keywords = "AML, amonafide (l-malate), cytarabine (ARA-C), MDR proteins, multidrug resistance, N-acetyltransferase 2 (NAT2), naphthalimides, P-glycoprotein, secondary AML/treatment-related AML (sAML/tAML), topoisomerase II inhibitor",
author = "Freeman, {Ciara L.} and Swords, {Ronan T} and Giles, {Francis J.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1586/ehm.11.68",
language = "English",
volume = "5",
pages = "17--26",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Amonafide

T2 - A future in treatment of resistant and secondary acute myeloid leukemia?

AU - Freeman, Ciara L.

AU - Swords, Ronan T

AU - Giles, Francis J.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Development of the novel topoisomerase II inhibitor, amonafide, began almost 40 years ago. The drug was selected for further investigation owing to evidence of marked antineoplastic efficacy in preclinical models of cancer. When its usefulness in the treatment of various solid malignancies proved limited, focus was shifted to establishing its use as an antileukemic agent, specifically against secondary and treatment-associated acute myeloid leukemia (AML). While Phase I and II studies gave rise to hopes that amonafide might hold the key to treating older patients, including those with multidrug resistant, cytogenetically unfavorable secondary and treatment-associated AML, when used in combination with cytarabine, it failed to demonstrate a survival advantage over standard-of-care therapy in randomized studies. This article will outline the development of amonafide from the laboratory to the bedside and discuss the potential place that this agent has in the current management of AML.

AB - Development of the novel topoisomerase II inhibitor, amonafide, began almost 40 years ago. The drug was selected for further investigation owing to evidence of marked antineoplastic efficacy in preclinical models of cancer. When its usefulness in the treatment of various solid malignancies proved limited, focus was shifted to establishing its use as an antileukemic agent, specifically against secondary and treatment-associated acute myeloid leukemia (AML). While Phase I and II studies gave rise to hopes that amonafide might hold the key to treating older patients, including those with multidrug resistant, cytogenetically unfavorable secondary and treatment-associated AML, when used in combination with cytarabine, it failed to demonstrate a survival advantage over standard-of-care therapy in randomized studies. This article will outline the development of amonafide from the laboratory to the bedside and discuss the potential place that this agent has in the current management of AML.

KW - AML

KW - amonafide (l-malate)

KW - cytarabine (ARA-C)

KW - MDR proteins

KW - multidrug resistance

KW - N-acetyltransferase 2 (NAT2)

KW - naphthalimides

KW - P-glycoprotein

KW - secondary AML/treatment-related AML (sAML/tAML)

KW - topoisomerase II inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84856240667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856240667&partnerID=8YFLogxK

U2 - 10.1586/ehm.11.68

DO - 10.1586/ehm.11.68

M3 - Article

C2 - 22272701

AN - SCOPUS:84856240667

VL - 5

SP - 17

EP - 26

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 1

ER -